Inlexzo (gemcitabine intravesical system): promising data but key questions remain
World Journal of Urology · 2025
DOI: 10.1007/s00345-025-05955-0 ↗At a glance
Leserbrief in World Journal of Urology, 2025. Written by Zarmeen Azhar and 1 co-authors. Institution: Karachi Medical and Dental College, Karachi, Pakistan. zarmeen.azhar123@gmail.com. Major MEDLINE topics: Antimetabolites, Antineoplastic, Carcinoma in Situ, Deoxycytidine, Urinary Bladder Neoplasms. Cited 3 times so far (Crossref); 5 references.
Abstract (original language)
The FDA approval of Inlexzo (gemcitabine intravesical system, formerly TAR-200) for BCG-refractory non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ is a milestone achievement in bladder-sparing therapy. Outcomes from the SunRISe-1 trial showed an outstanding 3-month complete response rate of 82%, and sustainability in more than half of responders at 12 months. Yet enthusiasm must be balanced with significant cautions: lack of comparator arm, immature long-term survival data, and practical issues with indwelling intravesical delivery, risk of infection, and access in low-resource environments. While Inlexzo is promising in a population where alternatives are scarce, its place must be clarified by longer-term follow-up, randomized comparisons versus systemic and intravesical therapies, and real-world experience. Prior to that, clinicians must utilize open counseling and shared decision-making.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Karachi Medical and Dental College, Karachi, Pakistan. zarmeen.azhar123@gmail.com.
- Karachi Medical and Dental College, Karachi, Pakistan.
Cite
APA
Azhar, Z., & Sadia, Z. (2025). Inlexzo (gemcitabine intravesical system): promising data but key questions remain. World Journal of Urology. https://doi.org/10.1007/s00345-025-05955-0
Vancouver
Azhar Z, Sadia Z. Inlexzo (gemcitabine intravesical system): promising data but key questions remain. World Journal of Urology. 2025. doi:10.1007/s00345-025-05955-0
BibTeX
@article{Azhar2025,
author = {Azhar, Zarmeen and Sadia, Zehra},
title = {Inlexzo (gemcitabine intravesical system): promising data but key questions remain},
journal = {World Journal of Urology},
year = {2025},
doi = {10.1007/s00345-025-05955-0}
}
EUVIMED